DUBLIN–(BUSINESS WIRE)–The “Alpha-1 Antitrypsin Drugs – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.
Global Alpha-1 Antitrypsin Drugs Market to Reach $2 Billion by 2027
Amid the COVID-19 crisis, the global market for Alpha-1 Antitrypsin Drugs estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 9.6% over the period 2020-2027.
The U.S. Market is Estimated at $319.3 Million, While China is Forecast to Grow at 9% CAGR
The Alpha-1 Antitrypsin Drugs market in the U.S. is estimated at US$319.3 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$354.1 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.
(Total 43 Featured):
- Abeona Therapeutics
- Alnylam Pharmaceuticals
- Applied Genetic Technologies Corp
- Arrowhead Research Corporation
- Baxalta
- Baxter
- CSL Behring
- Grifols
- Kamada
- Shire
- Takeda Pharmaceutical Company Limited
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- World…
